Market open
Altimmune/$ALT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Altimmune
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Ticker
$ALT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
59
Website
Altimmune Metrics
BasicAdvanced
$530M
Market cap
-
P/E ratio
-$1.60
EPS
0.11
Beta
-
Dividend rate
Price and volume
Market cap
$530M
Beta
0.11
52-week high
$14.84
52-week low
$2.32
Average daily volume
2M
Financial strength
Current ratio
11.296
Quick ratio
11.08
Long term debt to equity
0.995
Total debt to equity
1.221
Interest coverage (TTM)
-2,947.97%
Management effectiveness
Return on assets (TTM)
-34.09%
Return on equity (TTM)
-63.29%
Valuation
Price to revenue (TTM)
1,157.846
Price to book
3.47
Price to tangible book (TTM)
3.47
Price to free cash flow (TTM)
-6.624
Growth
Revenue change (TTM)
-604.94%
Earnings per share change (TTM)
-1.98%
3-year revenue growth (CAGR)
-59.65%
3-year earnings per share growth (CAGR)
-4.23%
What the Analysts think about Altimmune
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Altimmune stock.
Altimmune Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Altimmune Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Altimmune News
AllArticlesVideos
How Altimmune Could Grab a Big Chunk of the GLP-1 Market
MarketBeat·3 hours ago
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
GlobeNewsWire·1 day ago
Altimmune to Participate at Two Upcoming Investor Conferences
GlobeNewsWire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Altimmune stock?
Altimmune (ALT) has a market cap of $530M as of November 08, 2024.
What is the P/E ratio for Altimmune stock?
The price to earnings (P/E) ratio for Altimmune (ALT) stock is 0 as of November 08, 2024.
Does Altimmune stock pay dividends?
No, Altimmune (ALT) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Altimmune dividend payment date?
Altimmune (ALT) stock does not pay dividends to its shareholders.
What is the beta indicator for Altimmune?
Altimmune (ALT) has a beta rating of 0.11. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.